Rotator Cuff Tears: What the Evidence Supports, and Where It Runs Out

*Which tear you have changes everything — and almost all the good evidence for biologics is about using them with surgery, not instead of it.*

The Problem

You reach for a mug on the top shelf and the pain stops you cold. Putting on a shirt becomes a morning struggle. Lying on that side at night is impossible.

Rotator cuff problems steal sleep and function, and the prospect of surgery — long rehabilitation, uncertain outcome, the risk of a repair that fails — sends a lot of people looking for something else.

This article sets out what the evidence actually supports, including the parts that argue against the treatment we sell.

Start Here: Which Problem Do You Have?

"Shoulder pain" covers several distinct conditions whose evidence bases point in different directions.

Getting this wrong in either direction causes harm. Treating a locked, acute, traumatic full-thickness tear conservatively wastes the window in which repair works best. Treating degenerative subacromial pain surgically exposes someone to an operation that did not outperform a sham.

Tear categories in detail

Partial-thickness tears involve part of the tendon thickness — bursal surface, articular surface, or intratendinous. Function is often reasonably preserved with pain on specific movements.

Full-thickness tears are complete discontinuity, ranging from small defects to massive multi-tendon tears. The larger the tear, the greater the impairment and the harder the treatment.

Degenerative tears develop gradually, typically over 60. Traumatic tears follow an acute injury and may occur in younger patients with otherwise healthy tendon.

⚠️ Two features change the plan more than tear size alone:

• Fatty infiltration, graded by the Goutallier classification on MRI. Advanced fatty infiltration (Goutallier 3-4) means the muscle has been replaced by fat, and that change does not reverse. It predicts poor healing after repair and rules out biologic augmentation as a meaningful option.
• Retraction — how far the torn tendon has pulled back from its attachment.

Ask for both when your imaging is reported. They are the difference between a repairable tear and an irreparable one.

Understanding Rotator Cuff Anatomy

The rotator cuff is four muscles and their tendons — supraspinatus (initiates arm raising to the side), infraspinatus (external rotation), teres minor (assists external rotation), and subscapularis (internal rotation, arm across the body). Together they stabilise the humeral head and enable overhead movement.

The supraspinatus bears the greatest stress during overhead activity and fails most often, which is why the first symptom is usually pain reaching upward or outward.

What the Research Says

The most important framing on this page

*Almost every favourable study of biologics in the rotator cuff gave the biologic together with a surgical repair.* Both groups had the operation; one also received PRP or cells. That design can tell you whether the biologic adds something to surgery. It cannot tell you whether the biologic replaces surgery, because nobody in those trials went without it.

This matters because the headline result — reduced retear rate — is only defined in people who had a repair. A tendon that was never repaired cannot re-tear.

PRP: the fullest picture

Feltri et al. (2023)¹, a Level I systematic review and meta-analysis of 36 RCTs and 2,443 patients (20 surgical, 16 conservative), is the best single source available:

The authors' own caveat: "the high heterogeneity of products and studies remains a significant limitation to fully understanding PRP potential in this field."

Roy et al. (2025)³ reviewed 30 RCTs (~2,500 participants) in rotator cuff tendinopathy — a tendon problem, not a tear. PRP significantly reduced pain and improved function in the short term versus placebo and corticosteroid, but long-term benefits beyond 12 months were limited, with retear rates and function similar to control groups.

⚠️ We are flagging the source quality ourselves: that review appears in a journal whose scope is case reports. Its conclusion agrees with Feltri's, which is the stronger record, so we rely on Feltri.

Mesenchymal stem cells as surgical augmentation

Vieira Ferreira et al. (2025)² reviewed MSC injection as an augmentation tool in rotator cuff repair — 5 studies, 228 patients, mean age 59.3. Three studies used bone marrow MSCs, two used adipose MSCs.

• No difference in clinical or functional outcomes between repair with MSCs and repair alone
• A protective effect against retear was seen: RR 0.52 (95% CI 0.27-0.98) at mid-term and RR 0.24 (95% CI 0.11-0.53) at 10 years

⚠️ Three qualifications that change how much weight this carries, all stated by the authors:

1. This was not a meta-analysis. "We were not able to perform a meta-analysis due to the high clinical heterogeneity across the included studies… and to the very low number of available comparative studies." Each relative risk above comes from a single study, and a third study found no significant protective effect (retear 9% vs 17%).
2. The authors' own bottom line: "The literature on this topic is still preliminary and the quality and certainty [of the evidence is low]."
3. None of the five studies used umbilical cord-derived MSCs.

⚠️ A note on a statistic you may see quoted elsewhere. These studies report large within-group improvements — patients much better after treatment than before, by multiples of the minimal clinically important difference. That measures the rotator cuff repair, which works. It is not evidence about the cells, because the comparison group had the same operation and improved too. When the between-group comparison is null, a large within-group number does not rescue it.

Biologics in large and massive tears

Goldenberg et al. (2020)⁴ reviewed the options for large and massive tears, which carry the highest retear risk. Their conclusions, stated as they wrote them:

• PRP: "Due to mixed results and a lack of standardization in high-quality studies, we cannot recommend PRP at this time as an adjunct to rotator cuff repair."
• Stem cells: "Stem cells have been the least studied to date, so it is difficult to give recommendations for or against their use at this time." Bone marrow and adipose stem cells improve tendon repair biomechanics in animal studies, but "evidence from human studies is lacking, especially in patients with large and massive tears."
• What they do endorse: extracellular matrix and synthetic scaffolds, acellular dermal allografts, and superior capsule reconstruction, "especially in situations where native tendon is compromised."

We are including this because it is the most direct assessment of our own product category in the hardest cases, and it does not support us. The interventions it does support are surgical.

Spicer et al. (2024)⁹ compared two adjunct combinations during repair — BMAC alone versus BMAC with PRP — across three studies. There was no significant difference (Cohen's d 2.35 vs 2.19; between-group d 0.16, p = 0.76), and the authors concluded that "given the lack of superiority and the small sample size, more research is required."

The evidence for cell therapy WITHOUT surgery

This is the question this page exists to answer, and the honest answer is that there is very little.

Hurd et al. (2020)⁵ is the only randomised controlled trial of a cell therapy given without surgical repair:

The authors described it as an initial safety and feasibility pilot and announced a confirmatory randomised trial of 246 patients.

⚠️ We checked what happened to that trial. ClinicalTrials.gov NCT02918136 is recorded as completed in December 2018 with an actual enrolment of 18 patients — not 246 — and no results have been posted. The confirmatory evidence was promised eight years ago and has not appeared.

Surgery's own evidence, where it has been tested against placebo

Two large trials randomised patients to a real operation or a placebo operation:

*CSAW (Beard et al., 2018, Lancet)⁶ — n=313, 32 UK hospitals. Arthroscopic subacromial decompression vs arthroscopy only (placebo) vs no treatment. Oxford Shoulder Score at 6 months: decompression 32.7 vs placebo arthroscopy 34.2, difference −1.3 (95% CI −3.9 to 1.3), p = 0.31. Both surgical groups beat no treatment by small margins the authors called "not clinically important." Their conclusion: the findings "question the value of this operation for these indications."*

*FIMPACT (Paavola et al., 2018, BMJ; 5-year follow-up 2021, BJSM)^7,8 — n=210, three arms: decompression, diagnostic arthroscopy (placebo), and exercise therapy. At 24 months no difference exceeded the minimal important difference. At 5 years: "ASD provided no benefit over diagnostic arthroscopy (or exercise therapy)."*

⚠️ What these trials do and do not show — this matters and is often overstated.

• They tested subacromial decompression for impingement and subacromial pain. CSAW explicitly excluded full-thickness rotator cuff tears.
• They therefore say nothing about rotator cuff repair for a tear, which remains indicated in the situations listed below.
• What they do establish is that for subacromial pain with intact tendons, surgery is not the answer — and that exercise therapy performed as well as surgery at 2 and 5 years.

Exercise therapy

Exercise therapy is the first-line treatment for rotator cuff related shoulder pain in current practice, and FIMPACT's exercise arm matched surgery at both 2 and 5 years^7,8.

⚖️ An honest qualification: recent syntheses find exercise therapy is not clearly superior to other conservative treatments. Liu et al. (2026)¹⁰ pooled 19 studies (n=1,349) and found no difference between exercise therapy and passive physical therapy for pain (SMD −0.14, 95% CI −1.25 to 0.96) or disability (SMD −0.06, −1.57 to 1.45) in the short term, at low certainty of evidence.

So: exercise therapy is first-line, it matches surgery, and its advantage over other conservative care is unproven. All three are true.

Treatment Options Compared

When surgery is the right answer

• Acute traumatic full-thickness tears in younger patients — time-sensitive; seek an opinion promptly
• Progressive weakness despite appropriate conservative treatment
• Occupational demands requiring maximum strength recovery
• Massive irreparable tears with cuff tear arthropathy — see below

Cuff tear arthropathy and reverse total shoulder arthroplasty

When a massive tear has been present for years, the humeral head migrates upward and the joint degenerates — rotator cuff tear arthropathy. The tendon cannot be repaired and no biologic will change that.

Reverse total shoulder arthroplasty is an established, effective operation for this, and it restores overhead function by re-engineering the joint so the deltoid does the work the cuff no longer can.

If you have a long-standing massive tear with weakness and loss of overhead reach, the referral you need is to a shoulder arthroplasty surgeon. That is a better use of your time and money than anything on this page.

Is This Right For You?

May be appropriate

• Partial-thickness or small full-thickness tears, after a genuine course of exercise-based rehabilitation has failed
• Patients already scheduled for surgical repair, considering augmentation — the setting with the most supportive evidence^1,2
• Patients who understand that the non-surgical evidence is a single 16-patient randomised trial using a different cell product⁵

Not appropriate

• ⛔ Acute traumatic full-thickness tear — this needs a prompt surgical opinion, not an injection
• ⛔ Massive, retracted tears with advanced fatty infiltration (Goutallier 3-4)
• ⛔ Cuff tear arthropathy — see reverse arthroplasty above
• ⛔ Active infection or systemic inflammatory conditions
• ⛔ Certain malignancies (requires individualised assessment)

The Sterling-Certified Approach

The 7-Night Treatment Protocol

Day 1: Assessment

• Comprehensive blood panel
• Review of imaging, including tear thickness, size, retraction and fatty infiltration grade
• Review of what rehabilitation has already been completed

Day 2+: Core treatment

• Up to 100 million umbilical cord-derived mesenchymal stem cells (UC-MSCs) — 50 million per session, split across two sessions where indicated
• Fresh, not frozen; 95%+ viability, with a Certificate of Analysis for the batch
• Image-guided delivery to the injured tendon

Days 3-7: Rehabilitation and review

• Structured rehabilitation — the component with the strongest evidence behind it^7,8
• Follow-up assessment and discharge planning

⚠️ Two things we want to be straightforward about.

On the cells. Cell counts, viability figures and session structure describe what we provide. They are not evidence of effect. None of the studies cited on this page used umbilical cord-derived MSCs — the human rotator cuff literature uses bone marrow and adipose cells. We use UC-MSCs because they are available without a harvest procedure and without a culture delay, which are practical advantages, not demonstrated clinical ones.

On what to expect. We are not going to publish a 30/60/90-day milestone schedule. The published evidence does not support a timetable, and our own patients' results are not evidence.

Additional therapies

Some patients are offered NK/NKT cell therapy (which requires a 14-21 day culture period), plasmapheresis, or cord blood plasma.

⚠️ There is no published evidence that any of these improves rotator cuff healing, and we make no such claim. They are offered on separate assessment for their own reasons, and none of them is a reason to choose this treatment.

Frequently Asked Questions

Can stem cells heal my torn rotator cuff?

There is no published evidence that injection alone produces structural healing of a rotator cuff tear. The best available data concerns symptom and function scores, not tendon continuity, and comes from a 16-patient trial using a different cell product⁵. Structural healing and symptomatic improvement are different claims, and only the second has any support.

Is it better than surgery?

That comparison has never been made. No trial has randomised patients to cell therapy versus rotator cuff repair. What has been studied is cells or PRP added to repair — where they reduce retear rates but do not improve clinical scores^1,2.

Should I have surgery for shoulder impingement?

Two placebo-surgery-controlled trials found subacromial decompression no better than a sham operation, and no better than exercise therapy at 5 years^6,7,8. If your tendons are intact and the diagnosis is impingement or tendinopathy, exercise therapy is the reasonable first step.

I have a massive tear and my arm barely lifts. What should I do?

See a shoulder arthroplasty surgeon. If you have cuff tear arthropathy, reverse total shoulder arthroplasty is an established operation with good outcomes, and it will do more for you than any injection.

You sell this. Why are you arguing against it?

We are describing the evidence accurately, including the parts against us. We think biologics are a reasonable option for a narrow group — mainly people already having a repair, and people with partial-thickness tears who have exhausted rehabilitation. Outside that group the case is weak, and you would find that out eventually anyway.

How does this compare to a cortisone injection?

The one randomised comparison found better shoulder scores at 24 and 52 weeks with adipose-derived cells than with corticosteroid, in 16 patients⁵. In that same trial, one patient in the corticosteroid group progressed to a full-thickness tear. Repeated corticosteroid injection is generally used sparingly around tendons for that reason.

Will I need multiple treatments?

There is no trial evidence on repeat dosing for this indication, so any recommendation for further treatment is a clinical judgement rather than a protocol derived from data.

Is the procedure painful?

The injection is done with local anaesthetic and is generally well tolerated. Post-injection soreness typically settles within 48-72 hours.

Are UC-MSCs safe?

Umbilical cord MSCs from certified laboratories undergo screening for infectious agents and viability confirmation. Reported adverse events in the published rotator cuff literature have been minimal — but that literature is small, and our own treatment numbers are not evidence of safety.

Take the Next Step

If you have an acute traumatic tear, or a massive tear with weakness and loss of overhead reach, see a shoulder surgeon first. Those are the two situations where delay costs you something.

Otherwise, the reasonable sequence is a proper course of exercise-based rehabilitation, then a conversation about what is left.

Schedule a consultation and the medical team will review your imaging — tear thickness, size, retraction and fatty infiltration grade — and tell you honestly which of these categories you are in, including when the answer is that we are not the right option.

Explore related conditions: See our articles on Elbow Tendinopathy, Wrist & Hand Conditions, Knee Pain & Osteoarthritis, and Hip Pain & Arthritis.